Article info
PDFSpecial populations
Review
Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
- Correspondence to Dr Callum Little; callumlittle{at}nhs.net
Citation
Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?
Publication history
- Received June 16, 2020
- Revision received July 19, 2020
- Accepted August 10, 2020
- First published August 19, 2020.
Online issue publication
January 09, 2022
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.